Skip to main content
OpenTrials
Completed

NCT Number: NCT05589584

N-acetyl Cysteine and Patients with Non-alcoholic Fatty Liver Disease

Effect of N-acetyl cysteine on markers of oxidative stress and insulin resistance in patients with Non-alcoholic fatty liver disease

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Simple Steatosis Non Fatty Liver

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

NHTMRI

Cairo, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males or females aged 18-60 years diagnosed with NAFLD

Exclusion criteria

  • History of alcohol consumption, drug addiction or the use of medications known to precipitate steatohepatitis.
  • Patients with schistosomiasis, active hepatitis B or C, autoimmune and diabetes mellitus.
  • current Consumption of any antioxidant supplements and hepatotoxic drug.
  • Pregnancy or lactation or expecting to get pregnant during the study.
  • Medical, psychological, or pharmacological factors interfering with the collection or interpretation of study data.
  • Active Cancer patients.
  • Anyone having hypersensitivity to N-acetylcysteine.
  • Anyone already taking N-acetylcysteine.

Treatment and study plan

N acetyl cysteine with weight reduction

Drug

high dose 2400mg/day

Primary outcomes

  1. assessment of the effect of NAC on leptin

    Time frame: 3 months

    leptin as insulin resistance marker in NAFLD

Secondary outcomes

  1. assessment of the effect of NAC on MDA

    Time frame: 3 months

    MDA as oxidative stress marker in NAFLD

Sponsors and collaborators

Lead sponsor

Ain Shams University

Other

Registry information

Official study title

Effect of N-acetyl Cysteine on Markers of Oxidative Stress and Insulin Resistance in Patients with Non-alcoholic Fatty Liver Disease

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Oct 21, 2022
Registry last updated
Oct 17, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.